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Summary Evidence-based medicine is a corner stone in treatment decision making
and large randomised, clinical trials are usually designed in order to provide highly
significant results. This study was conducted in order to find out to what extend a
‘‘real life’’ patient population with obstructive lung disease could fit into criteria
commonly used in clinical research trials. As a secondary aim of the study, we
wanted to compare the OLD population recruited from GP’s and specialist out-
patient clinics, respectively. Eight-hundred and seventy prospective OLD patients
were included. Criteria’s for selecting asthma patients to a clinical trial were,
absence of co-morbidity, FEV 50–85% of predicted, present or historical reversibility
12% last year, non-smoke or if ex-smoke a smoke burden less then 10 pack years. Only
5.4% of the study asthma patients met with these criteria. Additional criteria’s as
being symptomatic and regular use of inhaled corticosteroids reduced the numbers
of eligible asthma patients to 3.3% representing 1.3% of the entire population. The
same procedure was applied for the COPD patients, requesting a FEV1o70% of
predicted normal, significant smoke history (415 pack years) and absence of atopy.
This selected 17% of the COPD population, representing 7% of the entire population.
We conclude that ‘‘evidence based’’ treatment decisions for OLD are based on
studies which include a very small and highly selected fraction of this patient
population. It is questionable whether such data can extrapolated to a larger, ‘‘real
life’’ population of patients with obstructive lung disease. Moreover, we found
surprisingly minor differences between the Specialist and GP populations.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
During recent years, clinical decision making has
been directed away from the doctor’s clinical
experience towards a more evidence-based
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approach. The latter is exemplified by a number of
treatment guidelines with recommendations
graded according to the strength of scientific
evidence. The strongest category of evidence is
based on randomised controlled trials (RCTs),
including a large number of patients. However,
most of these clinical trials have been performed in
highly selected patient populations. The argument
for this strict selection of study subjects is to
secure that confounding factors do not conceal the
effect of the actual treatment. On the other hand,
a strictly selected patient population may not
necessarily allow extrapolation of the treatment
results to larger, unselected patient populations.
This is a major problem when treatment guidelines
are to be implemented in the everyday practice of
medical doctors.
Several guidelines for management of obstruc-
tive lung diseases (OLD) have been published.1,2
These guidelines are the result of thorough studies
of the current literature in the field of bronchial
asthma and chronic obstructive pulmonary disease
(COPD). The treatment recommendations are
mainly based on well-designed RCTs. However, it
is not known how representative these study
patients are for the majority of patients with
obstructive airway diseases. The aim of the present
study was to investigate what proportion of an
outpatient population with obstructive lung disease
that could actually have been included in a typical
randomised clinical trial on either asthma or COPD
patients. This might be of interest since, in every-
day medicine; the results of such trials are
implemented on a much broader spectre of
patients than the populations from which these
results are obtained.
All outpatients with obstructive lung disease
were consecutively recruited for the study from
three pulmonary specialist clinics and nine GP’s. All
participating doctors had previously recruited
asthma and/or COPD patients for clinical trials.
The investigators were asked to classify the
patients as having either asthma or COPD on a
10 cm free-graded visual analogue scale (VAS).
After being classified as having either asthma or
COPD the patients were subjected to regularly
employed selection criteria used in RCTs. Subse-
quently, the number of patients suitable for such
clinical trials was calculated. Our hypothesis was
that the typical study patients represent a small
minority of the ‘‘real life’’ population of patients
with obstructive lung disease. If so, the trials
providing high-grade evidence for global treatment
recommendations might be questioned as a tool for
guiding the treatment of a larger population of
patients. As a secondary aim of the study, we
wanted to compare the OLD population recruited
from GP’s and specialist out-patient clinics, re-
spectively.
Materials and methods
Patients
Nine GP’s and three hospital out-patient clinics
recruited consecutive out-patients with OLD for the
study. The centres were trained in an investigator
meeting to make sure that all the investigators
followed the same study procedure. Patients over
age 18 and a history of OLD were recruited
following an oral consent. All patients fulfilling
these criteria were prospectively included during
the period August 2001–January 2002. The patients
could only be included once.
Methods
All patients were interviewed by the investigator
following a structured questionnaire, and the
results were plotted in a form with tick boxes,
easy to complete.
Demographic data were collected, age, height,
gender and duration of OLD, smoke history and
history of hay fever and other significant co-
morbidity. Disease activity data included number
of awakenings due to respiratory symptoms last
month, use of rescue medication and other anti-
obstructive medication and also use of oral corti-
costeroids last 12 months. Baseline spirometry
values including reversibility data were registered.
The investigating physicians were asked to grade
the relative purity of disease by using a 10 cm free-
graded visual analogue scale (VAS) with bronchial
asthma and COPD as the extremes. A VAS score
0–o2.5 was regarded as bronchial asthma and a
score 47.5 as COPD. The group VAS 2.5–7.5
was classified as intermediate, non-classified OLD
(Table 1).
The study was approved by the National Regional
Ethic Committee.
Statistical analysis
Comparison of subgroups (GP vs. Hospital, asthma
vs. COPD) for categorical variables, were tested
using Fisher’s exact test. Comparison of the same
subgroups regarding continuously distributed vari-
ables was tested using the unpaired t-test. All tests
were performed two-sided, and a significance level
of 5% was used in all tests.
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Results
Study population
Eight-hundred and seventy out-patients were in-
cluded, 420 investigated by GP’s and 450 by lung
specialists. Three-hundred and thirty four patients
were diagnosed by the clinicians as having mainly
bronchial asthma (VASo2.5), and 366 patients
were diagnosed as mainly COPD patients
(VAS47.5). The remaining 170 patients were
regarded as being less clear-cut with regard to
type of obstructive lung disease (VAS 2.5–7.5)
(Table 1). More patients were diagnosed as having
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Table 1 Descriptive data from 870 prospective patients classified on a VAS scale as being pure asthma
(VASo2.5), COPD (VAS47.5) or having a mixed disease (VAS 2.5–7.5).
Asthma Mixed group COPD ALL
VAS 0–2.49
(n ¼ 334)
VAS 2.5–7.49
(n ¼ 170)
VAS 7.5–10
(n ¼ 366)
Total
(n ¼ 870)
n % n % n % n %
Age (mean and SD) 43.7 16.8 58.6 15.1 67.1 11.0 56.2 17.7
Gender (male) 124 37.1 59 34.7 182 54.2 365 42.0
History of hay fever 174 52.1 57 33.5 42 12.5 273 31.4
Current smoke 65 19.5 64 37.6 153 45.5 282 32.4
Previous smoker 75 22.5 60 35.3 172 51.2 307 35.3
Smoke burden 410 pack year 49 14.7 90 52.9 255 75.9 394 45.3
Baseline spirometry FEV1o70%
of pred
57 17.1 88 26.3 295 87.8 440 50.6
Baseline spirometry FVC o70%
of pred
23 6.9 36 10.8 172 51.2 231 26.6
Baseline spirometry FEV1 51–
85% of pred
124 37.1 100 29.9 157 46.7 381 43.8
Baseline spirometry FVC 51–85%
of pred
88 26.3 94 28.1 215 64.0 397 45.6
Historical reversibility 12%
within 12m
94 28.1 38 11.4 49 14.6 181 20.8
Significant co-morbidity 104 31.1 87 51.2 222 60.7 413 47.5
Cor Pulmonale 0 0.0 1 0.6 18 4.9 19 2.2
Hypertonia 27 8.1 29 17.1 66 18.0 122 14.0
Ischemic heart disease 13 3.9 17 10.0 74 20.2 104 12.0
Diabetes 11 3.3 14 8.2 23 6.3 48 5.5
Anxiety 15 4.5 18 10.6 26 7.1 59 6.8
Depression 12 3.6 16 9.4 31 8.5 59 6.8
Interstitia lung disease 5 1.5 4 2.4 6 1.6 15 1.7
Oral steroid courses last 12
months
86 25.7 45 26.5 130 35.5 261 30.0
Use of ihaled GCS 242 72.5 129 75.9 255 69.7 626 72.0
o400 mg/day 34 10.2 8 4.7 23 6.3 65 7.5
400–800 mg/day 151 45.2 83 48.8 152 41.5 386 44.4
4800 mg/day 46 13.8 36 21.2 65 17.8 147 16.9
Use of short-acting b 2 agonist 204 61.1 96 56.5 211 57.7 511 58.7
Average use o1 dose/day 97 29.0 25 14.7 44 12.0 166 19.1
Average use 1–2 doses/day 53 15.9 31 18.2 48 13.1 132 15.2
Average use 4 2 doses/day 46 13.8 35 20.6 101 27.6 182 20.9
Use of long-acting b 2 agonist 168 50.3 93 54.7 182 49.7 443 50.9
Regular use 126 37.7 71 41.8 173 47.3 370 42.5
Treatment PRN 29 8.7 13 7.6 13 3.6 55 6.3
Nocturnal awakening last
month
None 240 71.9 113 66.5 269 73.5 622 71.5
1–2 night weekly 53 15.9 30 17.6 48 13.1 131 15.1
42 nights weekly 39 11.7 24 14.1 46 12.6 109 12.5
Real life patients population with obstructive lung disease 13
COPD among the lung specialists than among the
GPs (52.4% vs. 31%, Po0.05) with a trend towards
more asthma patients in the GP population (30 vs.
47.4%). Significant co-morbidity was found in 31% of
the asthmatics and among 61% of the COPD
patients. While 52% of the patients with asthma
had a baseline FEV1s exceeding 85% of predicted,
this was found only in 3% of the COPD patients. In
contrast, 15% of the COPD patients had FEV1s less
than 30% of predicted compared to none among the
asthmatics. Seventy-three per cent of the asth-
matics were using regular inhaled corticosteroid
therapy and 50% where using long-acting beta-2
agonist compared to 70% and 50% among the COPD
patients. Twenty-six per cent of the asthmatics had
taken at least one course of oral steroids last 12
months compared to 36% among the COPD patients.
Thirty-two per cent of the patients were current
smoker, 19.3% among the asthmatics, 42% among
the COPD patients and 37.8% among those with
mixed disease. Twenty-five per cent of all current
smokers also had a history of hay fever, 48% in the
asthma group, 10% in the COPD group and 36%
among those with mixed disease.
Selection of asthma patients for a typical RCT
The inclusion criteria were applied on the group of
patients defined by the clinical investigator as
having asthma on the VAS scale (o2.5). The
selection criterion excluding most patients was a
requested FEV between 50% and 85% of predicted
excluding 62.9% of the asthma population, with 124
patients remaining (Table 2, Fig. 1). Other selection
criteria used in order of discriminating significance,
were historical reversibility of FEV1s 412% last 12
months (50 patients remaining), absence from
significant co-morbidity (32 patients remaining),
no current-smoking or for ex-smokers request of a
smoke burden of less then 10 pack-years (One pack-
year ¼ 20 cigarettes daily for 1 year.)(18 patients
left¼ 5.4% of those with VAS o2.5% and 2.1% of all
patients) (Table 3, Fig. 1). When the selection
criteria were further stressed demanding patients
on regular use of inhaled corticosteroids and having
symptomatic asthma (nocturnal symptoms at least
once weekly or use of beta-2 agonist at least once
daily) the numbers of eligible patients were
reduced to 15 and 11, respectively (3.3% left of
those with VASo2.5% and 1.3% of all patients).
Selection of COPD patients for a typical RCT
The inclusion criteria were applied on the group of
patients defined by the clinical investigator as
having COPD on the VAS scale (47.5). The selection
criterion excluding most patients was absence of
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Table 2 No. of eligible asthma patients after different selection criterias.
Asthma patients (VAS o2.5)
GP Specialist Total
No No No
All patients 199 % 135 % 334 %
No co-morbidity 137 68.8 90 66.7 227 68.0
FEV1 50–85% of pred 72 36.2 52 38.5 124 37.1
Rev 12% last year 42 21.1 52 38.5 94 28.1
Pack year o10 140 70.4 87 64.4 227 68.0
Regular use of ICS 149 74.9 93 68.9 242 72.5
Symptomatic asthma 135 67.8 96 71.1 231 69.2
Figure 1 Number of subjects remaining as eligible
asthma clinical trial patients, after applying various
selection criterias. (1) VAS o2.5 defining pure asthma
patients on a visual analogue scale from 0–10. (2) FEV
between 50% and 85% of predicted normal. (3) Historical
reversibility in FEV 12% within last 12 months. (4)
Absence of significant co-morbidity. (5) Non-smoker or
if previous smoker, a smoke burden less than 10 pack-
years. (6) Regular use of inhaled corticosteroids. (7)
Symptomatic asthma defined as either use of short acting
b2-agonist daily or nocturnal awakening due to asthma at
least once weekly.
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significant co-morbidity excluding 65.9% of the
COPD population, with 132 patients remaining
(Table 4). The patients should have an FEV
exceeding 30 and being less than 70% of predicted
normal (88 patients remaining). They should also
have a smoke history (current or past smoke) with
at least 15 pack years (71 patients remaining).
Moreover, the patient should not have a history of
hay fever (63 patients remaining; 17.2% of patients
with VAS 47.5% and 7.2% of all patients (Table 5,
Fig. 2)). If the smoke criterion was strengthened
requesting ongoing smoking, no further patients
were excluded.
Intermediate group (VAS 2.5–7.5), selection
for a typical RCT
The intermediate group represented as may
be expected an intermediate group of patients
between COPD and asthma (Table 1). Thirty-eight
per cent of the patients were current smoker
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Table 3 No. of asthma patients remaining after stepwise introduction of selection criterias.
Asthma patients (VAS o2.5)
GP Specialist Total
No No No
All patients 199 % 135 % 334 %
FEV1 50–85% of pred 72 36.2 52 38.5 124 37.1
Rev 12% last year 26 13.1 24 17.8 50 15.0
No co-morbidity 16 8.0 16 11.9 32 9.6
Pack year o10 11 5.5 7 5.2 18 5.4
Regular use of ICS 10 5.0 5 3.7 15 4.5
Symptomatic asthma 6 3.0 5 3.7 11 3.3
Table 4 No. of eligible COPD patients after different selection criterias.
COPD patients (VAS 7.5–10)
GP Specialist Total
No No No
All patients 130 % 236 % 366 %
No co-morbidity 41 31.5 91 38.6 132 36.1
Smoke or X-smoke 122 93.8 203 86.0 325 88.8
Pack year 415 118 90.8 175 74.2 293 80.1
No hay fever 117 90.0 192 81.4 309 84.4
FEV1 30–70% 87 66.9 154 65.3 241 65.8
FEV o30 13 10.0 41 17.4 54 14.8
Table 5 No. of COPD patients remaining after stepwise introduction of selection criterias.
COPD patients (VAS 7.5–10)
GP Specialist Total
No No No
All patients 130 % 236 % 366 %
No co-morbidity 41 31.5 91 70.0 132 36.1
FEV1 30–70% 29 22.3 59 45.4 88 24.0
Smoke or X-smoke 28 21.5 52 40.0 80 21.9
Pack year415 25 19.2 46 35.4 71 19.4
No hay fever 23 17.7 40 30.8 63 17.2
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compared to 19.5 of the asthmatics and 45.5 of the
COPD patients. Co-morbidity was present in 51% of
the patients compared to 31% of the asthmatics and
61% of the COPD patients.
When the same selection criteria’s was used for
this group as was done for the asthma and COPD
patients, 14 (8.2%) the fulfilled the COPD RCT
criteria’s and 2 (1%) fulfilled the asthma RCT
criterias. When the additional asthma criteria,
regular use of inhaled corticosteroids and presence
of nocturnal symptoms or daily use of rescue beta-2
agonist, was applied, only one patient was left.
OLD population; GP’s vs. specialist out-
patient clinics
Asthma patients (VASo2.5)
One hundred ninety-nine GP patients and 135
specialist patients were judged to having mainly
asthma (VASo2.5) (Table 6). Significantly, more
specialist patient had taken at least one oral
steroid course during the last 12 months (35% vs.
20%, Po0.004). The specialist patients also more
frequently used rescue beta-2 agonist. Seventy-
nine per cent of the specialist patients compared to
66% of the GP patients used rescue beta-2 agonist
at least once daily (Po0.02) and 20.7 vs. 9.5% used
42 doses daily (P¼ 0.006). The specialist patients
also more often reported more frequent nocturnal
awakening due to asthma, with 17% vs. 8%
(Po0.05) having 42 nights per week with noctur-
nal awakening. Reversibility to beta-2 agonist
(412%) during the last 12 months was also more
frequently reported among the specialist patients
(53% vs. 24%, Po 0.001).
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Figure 2 Number of subjects remaining as eligible COPD
clinical trial patients, after applying various selection
criterias. (1) VAS 47.5 defining pure COPD patients on a
visual analogue scale from 0–10. (2) Absence of sig-
nificant co-morbidity. (3) FEV between 30% and 70% of
predicted normal. (3) Smoker or previous smoker. (4) A
smoke burden of at least 15 pack-years. (5) No history of
hay-fever indicating presence of atopy.
Table 6 Characteristics of asthma patients seen by general practitioners compared to those seen by specialists.
Asthma
GP (n ¼ 199) Specialist (n ¼ 135) All (n ¼ 334) P
n % n % n %
Age (mean and range) 43.9 18–84 43.5 19–89 43.7 18–89 Ns
Gender (male) 69 34.7 55 40.7 124 37.1 Ns
History of hay fever 103 51.8 71 52.6 174 52.1 Ns
Current smoke 38 19.1 27 20.0 65 19.5 Ns
Smoke burden o10 pack year 140 70.4 87 64.4 227 68.0 Ns
Smoke burden 415 pack year 45 22.6 34 25.2 79 23.7 Ns
Baseline spirometry FEV1 51–85% 72 36.2 52 38.5 124 37.1 Ns
Baseline spirometry FVC 51–85% 46 23.1 42 31.1 88 26.3 Ns
Historical reversibility 42 21.1 52 38.5 94 28.1 0.0001
Significant co-morbidity 51 25.6 40 29.6 91 27.2 Ns
Oral steroid courses last 12 months 39 19.6 47 34.8 86 25.7 0.004
Use of ihaled GCS 149 74.9 93 68.9 242 72.5 Ns
o400 mg/day 21 10.6 13 9.6 34 10.2
400–800 mg/day 97 48.7 54 40.0 151 45.2 Ns
4800 mg/day 21 10.6 25 18.5 46 13.8
Use of short-acting b 2 agonist 122 61.3 82 60.7 204 61.1 Ns
Average use 42 doses/day 19 9.5 28 20.7 47 14.1 0.006
Use of long-acting b 2 agonist 97 48.7 71 52.6 168 50.3 Ns
Nocturnal awakening last month 49 24.6 45 33.3 94 28.1 Ns
1–2 night weekly 33 16.6 20 14.8 53 15.9
42 nights weekly 16 8.0 25 18.5 41 12.3
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Significant co-morbidity was equally reported
among the specialist compared to the GP patients
(30% vs.26%, P40.05).
COPD patients
One hundred twenty-eight GP patients and 234
specialist patients were judged to having mainly
COPD (VAS 47.5) (Table 7). Significantly more GP
patient had a smoke history with a smoke burden
exceeding 15 pack years (92 vs. 79%, Po0.001). In
all other aspects, the profile of the GP and
specialist patients was fairly the same.
Discussion
The current study shows that typical clinical study
patients with asthma or COPD represent a very
small fraction of the patient population being
treated by clinicians in everyday practice, regard-
less of whether the doctors are pulmonary physi-
cians or GPs.
The most important selection criterion regarding
COPD patients seems to be the presence of co-
morbidity, with more than 60% of the patients
having a disease potentially interfering with the
treatment. Thus, in addition to suffering from
other diseases, these patients are often using other
medication than anti-obstructive drugs. This might
have an impact on the risk of side effects, but also
on the clinical effect of the actual study drug
per se. The compliance will also be influenced by
the number of drugs being prescribed.3 Another
important selection criterion was severely reduced
lung function, i.e. FEV1 less than 30% of pre-
dicted.4–8 Little is known about how these patients
react on the various anti-obstructive drugs, but one
might anticipate that such patients could experi-
ence less effect of inhaled drugs due to their
reduced ventilation of the peripheral airways.9
COPD patients with atopy are often excluded
from clinical trials. It has been shown that the lung
function of these patients deteriorates faster than
in non-atopic COPD patients,10 and it has been
claimed that the underlining pathology in these two
groups of COPD patients, and thus, the effect of
drug treatment may be dissimilar.11 Even if most
studies on COPD patients are performed on patients
with a heavy smoking burden, patients who have
smoked less are treated with the drugs tested in
these clinical trials.
Eight per cent of all patients were recognised as
being smokers with concurrent atopy and 25% of all
smokers were recognised as atopic. Of those
subjects, 49% were regarded as pure asthmatics,
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Table 7 Characteristics of COPD patients seen by general practitioners compared to those seen by specialists.
COPD
VAS 47.5
GP (n ¼ 130) Specialist (n ¼ 236) All (n ¼ 366) P
n % n % n %
Age (mean and range) 67.8 36–88 66.7 24–91 67.1 24–91 Ns
Gender (male) 68 52.3 114 48.3 182 49.7 Ns
History of hay fever 12 9.2 30 12.7 42 11.5 Ns
Current smoke 62 47.7 91 38.6 153 41.8 Ns
Smoke burden 415 pack year 118 90.8 175 74.2 293 80.1 Ns
Baseline spirometry FEV1o70% 100 76.9 195 82.6 295 80.6 Ns
Historical reversibility 14 10.8 35 14.8 49 13.4 0.004
Significant co-morbidity 51 39.2 40 16.9 91 24.9 Ns
Oral steroid courses last 12 months 42 32.3 88 37.3 130 35.5 Ns
Use of ihaled GCS 89 68.5 166 70.3 255 69.7 Ns
o400 mg/day 3 2.3 20 8.5 23 6.3
400–800 mg/day 50 38.5 102 43.2 152 41.5
4800 mg/day 29 22.3 36 15.3 65 17.8
Use of short-acting b 2 agonist 74 56.9 137 58.1 211 57.7 Ns
Average use 42 doses/day 39 30.0 62 26.3 101 27.6 Ns
0.0
Use of long-acting b 2 agonist 72 55.4 120 50.8 192 52.5 Ns
Nocturnal awakening last month 39 30.0 58 24.6 97 26.5 Ns
1–2 night weekly 25 19.2 23 9.7 48 13.1
42 nights weekly 13 10.0 33 14.0 46 12.6
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10% as COPD and 41% as having a non-classified
OLD. Also in those patients being regarded as pure
asthmatics, it is a reasonable assumption that the
inflammation triggered by smoke exposure influ-
enced by the atopic sensitisation in one way or an
other may represent a mixed pathology demanding
special treatment strategies. Indeed, it has been
shown that, asthmatic patients who smoke seems
to respond less to inhaled corticosteroid therapy
compared to those who do not smoke.12–14
In many studies looking at lung function improve-
ment as a primary outcome, a sub-optimal lung
function is often required in order to allow further
lung function improvement. We have chosen 85% as
a commonly used criteria for upper limit of
predicted FEV, even though also a lower upper
limit, i.e. 80% of predicted, is commonly used.15–17
In the present study nearly 65% was excluded
because of a FEV exceeding 50–85% of predicted.
In clinical practice, these patients are also treated
with anti-asthmatic drugs; targeting asthma symp-
toms like exercise intolerability, nocturnal symp-
toms etc. and the documentation regarding
treatment effect on these patients are thus
limited. Reversibility was defined as improvement
in FEV1s of more than 12% following inhalation of a
beta-agonist. This criterion was more frequently
positive among the patients examined by pulmon-
ary physicians. One reason is probably that rever-
sibility testing was more frequently performed
among specialists than by GPs. Reversibility should
not be regarded as a static phenomenon, and it has
been shown that repeated reversibility testing in
the same patient over several days increases the
probability of getting at least one positive test.18
More specialist asthma patients had been taken
at least one course of oral steroids during the last
12 month. Moreover, they tended to use more
rescue beta-2 agonists and more frequently re-
ported nocturnal awakenings. This indicates a
slightly more severe disease in the group of
patients seen by the specialists. On the other hand,
the medications used were similar between the
groups both regarding regular use of glucocorticos-
teroid and long acting beta agonists. Moreover, the
lung function profile and the percentage of patients
with co-morbidity, was the same for both groups
(data not shown). Taken all this together, we found
surprisingly minor differences between the two
populations.
Most recent guidelines for COPD and asthma
treatment are referring the recommendations to
evidence collected from large RTC and or systema-
tic reviews. Even though a large randomised trial,
containing a large number of patients, provide
highly statistical significances, in favour of one drug
before the other, this does not necessarily imply
that the results can be extrapolated to a larger, less
selected patient population. The question also
remains, to what extent strictly selected RTC really
provides information that justifies the investments
made. The more strict, the criteria, the easier it
will be to predict the outcome, and a sufficient
number of patients will in most instances secure
enough power for to reach statistical significant
differences.
Before stating ‘‘high grade of evidence’’ we need
to consider to what extend the results are of
clinical significance as well as statistical signifi-
cance. And still, the important question remains;
can the results obtained in a strictly selected RCT
be applied to the entire target population, i.e. to
the patients we meet in our ‘‘every day’’ clinical
practice.
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